| Patents for C12N 15 - Mutation or genetic engineering; Dna or rna concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor (402,210) |
|---|
| 04/15/2004 | CA2484335A1 Use of molecules which interact with the haptoglobin receptor ligand binding |
| 04/14/2004 | EP1408334A1 Procalcitonin 3-116 |
| 04/14/2004 | EP1408333A2 Diagnosis and treatment of Alzheimer's disease |
| 04/14/2004 | EP1408123A1 A microorganism in which the fadR gene is knocked out and a process for producing L-threonine using the microorganism |
| 04/14/2004 | EP1408122A2 Methods and compositions for efficient nucleic acid sequencing |
| 04/14/2004 | EP1408117A1 Glycoprotein and process for producing the same |
| 04/14/2004 | EP1408114A1 Modular antigen-transporter-molecules (MAT-molecules) for modulating immune responses, corresponding constructs and methods and uses thereof |
| 04/14/2004 | EP1408113A1 Human type antihuman ige receptor antibody and antibody fragment |
| 04/14/2004 | EP1408112A1 MONOCLONAL ANTIBODY BINDING TO MT4−MMP CATALYTIC DOMAIN |
| 04/14/2004 | EP1408111A2 Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor |
| 04/14/2004 | EP1408110A2 Oligonucleotide mediated specific cytokine induction and in vivo protection from infection |
| 04/14/2004 | EP1408108A2 Cellulase producing actinomycetes, cellulase produced therefrom and method of producing same |
| 04/14/2004 | EP1408107A2 Chlorohydrin and hydroxycarboxylic ester asymmetric hydrolase gene |
| 04/14/2004 | EP1408090A1 Dibenzorhodamine dyes useful as fluorescent labelling agents |
| 04/14/2004 | EP1408050A1 A method of producing glucagon-like peptide 1(glp-1)7-36 and an glp-1 analogue |
| 04/14/2004 | EP1408049A2 A novel inositol 1,4,5-trisphosphate (IP3) receptor-binding protein and an IP3 indicator |
| 04/14/2004 | EP1408028A1 S-adenosyl methionine decarboxylase inhibition for the treatment of a herpes simplex virus infection |
| 04/14/2004 | EP1407788A2 Myoblast therapy for mammalian diseases |
| 04/14/2004 | EP1407787A1 Method of promoting nucleic acid transfer |
| 04/14/2004 | EP1407661A1 Transgenic animal transformed using green fluorescent protein gene |
| 04/14/2004 | EP1407269A2 A method for diagnosing a person having multiple sclerosis |
| 04/14/2004 | EP1407054A2 Expression system |
| 04/14/2004 | EP1407053A2 Dna microarrays comprising active chromatin elements and comprehensive profiling therewith |
| 04/14/2004 | EP1407052A2 Method for monitoring and modulating protein folding |
| 04/14/2004 | EP1407051A2 Universal method and composition for the rapid lysis of cells for the release of nucleic acids and their detection |
| 04/14/2004 | EP1407050A2 Method for rapid amplification of dna |
| 04/14/2004 | EP1407047A1 METHOD OF DETERMINING A CHEMOTHERAPEUTIC REGIMEN BASED ON GLUTATHIONE-S-TRANSFERASE Pi EXPRESSION |
| 04/14/2004 | EP1407044A2 Rna interference mediating small rna molecules |
| 04/14/2004 | EP1407038A2 A thermostable isomerase and use thereof, in particular for producing tagatose |
| 04/14/2004 | EP1407035A2 Process for the preparation of l-amino acids using strains of the enterobacteriaceae family which contain an attenuated aspa gene |
| 04/14/2004 | EP1407034A2 Recombination systems and a method for removing nucleic acid sequences from the genome of eukaryotic organisms |
| 04/14/2004 | EP1407033A1 Intergenic regions as insertion sites in the genome of modified vaccinia virus ankara (mva) |
| 04/14/2004 | EP1407032A1 Anti-neoplastic viral agents |
| 04/14/2004 | EP1407031A1 Transformation of eukaryotic cells by mobilizable plasmids |
| 04/14/2004 | EP1407030A2 Methods for large scale production of recombinant dna-derived tpa or k2s molecules |
| 04/14/2004 | EP1407029A2 Novel human kinases and polynucleotides encoding the same |
| 04/14/2004 | EP1407028A2 Process for the preparation of l-amino acids using strains of the enterobacteriaceae family which contain an enhanced suca or sucb gene |
| 04/14/2004 | EP1407027A2 Process for the preparation of l-amino acids using strains of the entenobacteriaceae familiy which contain an enhanced succ or sucd gene |
| 04/14/2004 | EP1407026A2 Process for the preparation of l-amino acids using strains of the enterobacteriaceae family which contain an enhanced phob or phor gene |
| 04/14/2004 | EP1407025A2 Process for the preparation of l-amino acids using strains of the enterobacteriaceae family which contain an enhanced male gene |
| 04/14/2004 | EP1407024A2 Process for the preparation of l-amino acids using strains of the enterobacteriaceae family which contain an enhanced phoe gene |
| 04/14/2004 | EP1407023A2 Group b streptococcus antigens and corresponding dna fragments |
| 04/14/2004 | EP1407022A2 Process for the preparation of l-amino acids using strains of the enterobacteriaceae family which contain an enhanced rsea or rsec gene |
| 04/14/2004 | EP1407021A2 Process for the preparation of l-amino acids using strains of the enterobacteriaceae family which contain an attenuated ugpb gene |
| 04/14/2004 | EP1407020A2 Stress-associated genetic products from ashbya gossypii |
| 04/14/2004 | EP1407019A2 Intestinal proteins |
| 04/14/2004 | EP1407018A2 Human proteins, polynucleotides encoding them and methods of using the same |
| 04/14/2004 | EP1407017A2 Human tumor necrosis factor receptor |
| 04/14/2004 | EP1407016A2 Compositions and methods relating to breast specific genes and proteins |
| 04/14/2004 | EP1407015A2 Compositions and methods relating to breast specific genes and proteins |
| 04/14/2004 | EP1407014A2 Screening method for attenuating or virulence defective microbial cells |
| 04/14/2004 | EP1407013A1 Mutations in ion channels |
| 04/14/2004 | EP1407012A1 Methods of creating genetic diversity |
| 04/14/2004 | EP1407011A2 Human hyperpolarization-activated cyclic nucleotide-gated cation channel hcn1 |
| 04/14/2004 | EP1407010A1 Regulation of human aminopeptidase n |
| 04/14/2004 | EP1407009A2 Hydrolase enzymes and their use in kinetic resolution |
| 04/14/2004 | EP1407007A1 Attenuated circovirus |
| 04/14/2004 | EP1407006A1 Method for the recovery and purification of poxviruses from infected cells |
| 04/14/2004 | EP1407005A2 Integrative assays for monitoring molecular assembly events |
| 04/14/2004 | EP1407004A2 Ex-vivo priming for generating cytotoxic t lymphocytes specific for non-tumor antigens to treat autoimmune and allergic disease |
| 04/14/2004 | EP1407002A2 A bioprocess for the generation of cells derived from spheroid-forming cells |
| 04/14/2004 | EP1407000A4 Transformation method and transgenic plants produced thereby |
| 04/14/2004 | EP1407000A2 Transformation method and transgenic plants produced thereby |
| 04/14/2004 | EP1406997A2 A mouse unable to express functional alpha-4 integrin protein, and methods for assaying compounds or agents for alpha-4 integrin protein antagonist activity and a genetic marker for evaluating efficacy of modulators of signaling activity of a vla-4 receptor |
| 04/14/2004 | EP1406931A2 Modification of human variable domains |
| 04/14/2004 | EP1406930A2 Isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof |
| 04/14/2004 | EP1406929A2 Glycoprotein vi fusion proteins |
| 04/14/2004 | EP1406928A1 Ntb-a, a surface molecule involved in natural killer cells activity |
| 04/14/2004 | EP1406925A2 Survivin interacting protein tpr1 |
| 04/14/2004 | EP1406923A2 Histidine phosphatase interacting protein with 180kd |
| 04/14/2004 | EP1406917A1 Human albumin animal models for drug evaluation, toxicology and immunogenicity studies |
| 04/14/2004 | EP1406916A2 Genes associated with mechanical stress, expression products therefrom, and uses thereof |
| 04/14/2004 | EP1406915A2 Antisense modulation of transforming growth factor beta receptor ii expression |
| 04/14/2004 | EP1406906A1 Heteroaryl substituted fused bicyclic heteroaryl compounds as gabaa receptor ligands |
| 04/14/2004 | EP1406720A1 Buffers for electrophoresis and use thereof |
| 04/14/2004 | EP1406668A1 Composite oncolytic herpes virus vectors |
| 04/14/2004 | EP1406667A2 METHODS FOR INCREASING i IN VIVO /i EFFICACY OF OLIGONUCLEOTIDES AND INHIBITING INFLAMMATION IN MAMMALS |
| 04/14/2004 | EP1406666A2 Adenoviral vectors with cell type specificity for mesenchymal cells |
| 04/14/2004 | EP1406657A1 A novel engineered superantigen for human therapy |
| 04/14/2004 | EP1406653A2 T cell regulatory genes and methods of use thereof |
| 04/14/2004 | EP1406645A2 Novel human transporter proteins and polynucleotides encoding the same |
| 04/14/2004 | EP1406644A2 Modified proteins, designer toxins, and methods of making thereof |
| 04/14/2004 | EP1406573A2 Conditioned cell culture media and uses thereof |
| 04/14/2004 | EP1406561A2 Tissue engineered heart valve |
| 04/14/2004 | EP1406518A2 Modifying nicotine and nitrosamine levels in tobacco |
| 04/14/2004 | EP1406493A1 Administration of agents via the pept-2 transporter |
| 04/14/2004 | EP1406489A2 Eukaryotic genes involved in adult lifespan regulation |
| 04/14/2004 | EP1406484A2 Anti-apoptosis genes and methods of use thereof |
| 04/14/2004 | EP1406483A1 Genes for modifying plant traits iv |
| 04/14/2004 | EP1406482A2 Cotton event moni5985 and compositions and methods for detection |
| 04/14/2004 | EP1366057A4 Reagents for oligonucleotide cleavage and deprotection |
| 04/14/2004 | EP1259617B1 Bunyaviridal reaper proteins and uses therefor |
| 04/14/2004 | EP1222297B1 Elongase promoters for the tissue-specific expression of transgenes in plants |
| 04/14/2004 | EP1209971A4 Charge reversal of polyion complexes |
| 04/14/2004 | EP1200578B1 Method for rnase- and organic solvent-free plasmid dna purification using tangential flow filtration |
| 04/14/2004 | EP1181038B1 Novel indications of mannan-binding lectin (mbl) in the treatment of immunocompromised individuals |
| 04/14/2004 | EP1121426B1 Method for triggering apoptosis in cells |
| 04/14/2004 | EP1098982B1 Use of glucosylglycerol phosphate synthase gene for producing the low-molecular protective substance glucosylglycerol in plants |
| 04/14/2004 | EP1036185B1 Proteinase inhibitor fusion proteins |
| 04/14/2004 | EP1021541B1 Amino-terminally truncated mcp-2 as chemokine antagonists |